FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Ampligen | Chronic Fatigue Syndrome | PHASE3 | COMPLETED |
| αDC1 Vaccine | Ovarian Cancer | PHASE2 | NOT_YET_RECRUITING |
| Alferon LDO | HIV Infections | PHASE2 | TERMINATED |
| Rintatolimod | Prostate Adenocarcinoma | PHASE2 | ACTIVE_NOT_RECRUITING |
| Recombinant Interferon Alfa-2b | Prostate Adenocarcinoma | PHASE2 | ACTIVE_NOT_RECRUITING |
| poly I-poly C12U | HIV Seropositivity | PHASE2 | COMPLETED |
| Pembrolizumab | Ovarian Cancer | PHASE2 | NOT_YET_RECRUITING |
| Paclitaxel | Ovarian Cancer | PHASE2 | NOT_YET_RECRUITING |
| EC Aspirin | Prostate Adenocarcinoma | PHASE2 | ACTIVE_NOT_RECRUITING |
| Cisplatin | Ovarian Cancer | PHASE2 | NOT_YET_RECRUITING |
AIM holds $5.8M in cash and burns about $2.4M/quarter from operations, giving an estimated runway of 7.4 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for AIM free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-03-16 | CHEMEROW DAVID I. |
Purchase | $0 |
| 2026-03-16 | CHEMEROW DAVID I. |
Sale | $0 |
| 2026-03-16 | Equels Thomas K |
Purchase | $0 |
| 2026-03-16 | Equels Thomas K |
Sale | $0 |
| 2026-03-10 | CHEMEROW DAVID I. |
Purchase | $625,000 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for AIM and 2 more tickers of your choice.
Create Free Account →